M&A Corner
Lilly Completes Acquisition of DICE Therapeutics15 Aug 2023
Eli Lilly and Company (NYSE: LLY) has successfully finalized its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE), broadening its immunology... Continue Reading
|
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity15 Aug 2023
Carmell Corporation (Nasdaq: CTCX) has successfully completed its merger with Axolotl Biologix, a regenerative medicine company focused on soft tissue... Continue Reading
|
Transcat Accelerates the Growth of Its High Margin Rental Business with the Acquisition of Axiom Test Equipment, Inc.15 Aug 2023
Transcat, Inc. has completed the acquisition of Axiom Test Equipment, Inc., a prominent Electronic Test Equipment rental provider in the... Continue Reading
|
InComm Payments Acquires AI-Powered HSA Solution Zenda15 Aug 2023
InComm Payments has acquired Zenda, an AI-powered solution for HSAs and FSAs. This move aligns with InComm’s goal of aiding... Continue Reading
|
Neurophth Secures Nearly 95 Million USD in Series C+ Financing for Gene Therapy Clinical Trials15 Aug 2023
China’s prominent gene therapy firm for ophthalmic disorders, Neurophth Therapeutics, has successfully concluded a Series C+ funding round, securing nearly... Continue Reading
|
Tango Therapeutics Announces $80 Million Private Placement Financing15 Aug 2023
Clinical-stage biotech company Tango Therapeutics (NASDAQ: TNGX) is set to privately issue around 15.5 million shares of common stock or... Continue Reading
|
WindRose Portfolio Company Healthmap Raises $100 Million to Continue Fighting Kidney Disease15 Aug 2023
Healthmap Solutions, a kidney disease-focused national population health management company and a portfolio firm of WindRose Health Investors, has secured... Continue Reading
|
Robotics + Heart Valve Startup, Capstan Medical Raises $31.4M15 Aug 2023
Santa Cruz-based Capstan Medical, a developer of minimally invasive heart valve disease technology, secured a $31.4M Series B funding round... Continue Reading
|
Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China15 Aug 2023
Antengene and Hansoh Pharma have established a collaboration to enhance the commercialization of XPOVIO® in mainland China. XPOVIO®, a groundbreaking... Continue Reading
|
Marius Pharmaceuticals Partners with Smartway to Design and Manage the Global Early Access Program for KYZATREX™ (testosterone undecanoate)15 Aug 2023
Marius Pharmaceuticals and Smartway Pharmaceuticals have forged a strategic partnership to combat global hypogonadism. They will launch an Early Access... Continue Reading
|